Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (NYSE:BMY)

Statement of Comprehensive Income

Beginner level

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Bristol-Myers Squibb Co., consolidated statement of comprehensive income

US$ in millions

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Net earnings (loss) (8,995) 3,460  4,947  975  4,507 
Derivatives qualifying as cash flow hedges (256) (32) 70  (57) 4 
Pension and postretirement benefits (75) 1,203  53  214  (17)
Available-for-sale securities 5  36  (25) 39  16 
Foreign currency translation 7  35  (254) 18  (38)
Other comprehensive income (loss) (319) 1,242  (156) 214  (35)
Comprehensive income (loss) (9,314) 4,702  4,791  1,189  4,472 
Comprehensive (income) loss attributable to noncontrolling interest (20) (21) (27) 32  (50)
Comprehensive income (loss) attributable to BMS (9,334) 4,681  4,764  1,221  4,422 

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

Comprehensive income item Description The company
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co.’s net earnings (loss) attributable to BMS decreased from 2018 to 2019 and from 2019 to 2020.
Comprehensive income (loss) attributable to BMS Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Bristol-Myers Squibb Co.’s comprehensive income (loss) attributable to BMS decreased from 2018 to 2019 and from 2019 to 2020.